Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study

CONCLUSION: Despite 2.5-times longer delays, patients with early-stage estrogen receptor-positive breast cancer receiving neoadjuvant endocrine therapy did not experience pathologic upstaging during the COVID-19 pandemic. These findings may support the use of neoadjuvant endocrine therapy in similar patients if delays to surgery are projected.PMID:34862071 | DOI:10.1016/j.surg.2021.10.033

Source: Cancer Control - December 4, 2021 Category: Cancer & Oncology Authors: Élise Di Lena Brent Hopkins Stephanie M Wong Sarkis Meterissian Source Type: research